C
Certa Therapeutics
Developer of kidney disease treatments. The company's drugs block a receptor, a key driver of fibrosis (scarring) of the kidney which leads to kidney failure and ultimately dialysis or kidney…
About Certa Therapeutics
Certa Therapeutics is a clinical-stage biotechnology company that develops precision therapies for inflammatory and fibrotic diseases. The company focuses on identifying patients who will respond best to specific treatments through genetic information, a field known as precision medicine.
Its main drug candidate, FT011 (asengeprast), is an oral therapy for treating chronic fibrosis in various organs. This drug targets a G protein-coupled receptor (GPCR) known as GPR68, which plays a role in fibrosis. The company has secured orphan drug designation in the EU for FT011 for the treatment of systemic sclerosis.
Certa Therapeutics operates in the biotechnology sector, specifically in the niche of anti-fibrotic treatments. Its business model revolves around the research and development of these novel therapies, with the ultimate goal of bringing them to market to treat patients with serious conditions like scleroderma and chronic kidney disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Melbourne, Australia
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 62.2/100
- Industry
- Health, Travel
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Dec 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Oct 2022 | $32K | — | Innovation Connections | — |
| GRANT✓Other financing | Jul 2021 | $32K | — | Innovation Connections | — |
Growth signals
Latest recorded traffic for Certa Therapeutics is 3K monthly website visits, up 150% over the last three months. Certa Therapeutics's team declined 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innovation Connections
Series A2 investors entered at this stage
Brandon Capital Partners
Uniseed Ventures
Other known investors3 additional known investors
University of Melbourne
Stoic Venture Capital
Takeda
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Certa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Certa Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.